Page last updated: 2024-08-24

goralatide and ramipril

goralatide has been researched along with ramipril in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Azizi, M; Bissery, A; Floch, A; Guyene, TT; Ménard, J; Ozoux, ML; Peyrard, S	1
Bombardi, C; Castoldi, G; Corradi, B; di Gioia, CR; Leopizzi, M; Mancini, M; Perego, C; Perego, L; Perlini, S; Stella, A; Zerbini, G	1
Bombardi, C; Castoldi, G; Corradi, B; di Gioia, CR; Leopizzi, M; Maestroni, S; Preziuso, C; Stella, A; Zerbini, G	1

Trials

1 trial(s) available for goralatide and ramipril

Article	Year
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clinical pharmacology and therapeutics, 2006, Volume: 79, Issue:1 Topics: Adolescent; Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biotransformation; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Humans; Irbesartan; Male; Natriuresis; Oligopeptides; Peptidyl-Dipeptidase A; Protease Inhibitors; Ramipril; Renin; Renin-Angiotensin System; Single-Blind Method; Tetrazoles	2006

Article

Year

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.

Clinical pharmacology and therapeutics, 2006, Volume: 79, Issue:1

Topics: Adolescent; Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biotransformation; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Humans; Irbesartan; Male; Natriuresis; Oligopeptides; Peptidyl-Dipeptidase A; Protease Inhibitors; Ramipril; Renin; Renin-Angiotensin System; Single-Blind Method; Tetrazoles

2006

Other Studies

2 other study(ies) available for goralatide and ramipril

Article	Year
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clinical science (London, England : 1979), 2009, Oct-26, Volume: 118, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fibrosis; Heart Ventricles; Hypoglycemic Agents; Insulin; Male; Myocardium; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley; Smad Proteins; Transforming Growth Factor beta1	2009
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. American journal of nephrology, 2013, Volume: 37, Issue:1 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Growth Inhibitors; Kidney Glomerulus; Male; Membrane Proteins; Nephrosclerosis; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley	2013

Article

Year

Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.

Clinical science (London, England : 1979), 2009, Oct-26, Volume: 118, Issue:3

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fibrosis; Heart Ventricles; Hypoglycemic Agents; Insulin; Male; Myocardium; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley; Smad Proteins; Transforming Growth Factor beta1

2009

Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.

American journal of nephrology, 2013, Volume: 37, Issue:1

Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Growth Inhibitors; Kidney Glomerulus; Male; Membrane Proteins; Nephrosclerosis; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley

2013